Telesis Therapeutics

What Telesis Therapeutics does

Telesis Therapeutics is a privately-held, for-profit therapeutics company headquartered in Philadelphia, United States, founded in 2015. Per its public-facing description, the company develops and commercializes "breakthrough scientific discoveries" and prepares these assets for clinical translation, positioning it as a translational biotech focused on moving early-stage scientific findings toward investigational or clinical-stage programs. The company is led by Maurice T. Hampton, who serves as Executive Chairman and CEO.

The company operates with a small team of 1-10 employees, indicating an early-stage or lean operating model typical of preclinical or seed-stage biotech entities. No specific product candidates, therapeutic modalities, target indications, platform technologies, or pipeline assets are disclosed in the available data, and the corporate website did not return scrapable content beyond a verification page. No pricing model, revenue mechanism, licensing terms, or customer agreements are documented, consistent with a pre-commercial entity whose monetization would likely depend on future out-licensing, partnerships, or asset sales to larger pharma rather than direct product sales.

There is no disclosed information on funding rounds, capital raised, investors, partnerships, geographic footprint beyond the Philadelphia headquarters, or scientific advisors. The absence of these signals in the available data set is itself a material data point: it suggests limited public disclosure, a low public profile, or a very early stage of development. Any investment-grade assessment of Telesis Therapeutics should be treated as provisional given the thin evidence base.

Name

Telesis Therapeutics

Website

https://telesistherapeutics.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Short description

Telesis Therapeutics is a privately-held Philadelphia biotech founded in 2015 that develops and commercializes breakthrough scientific discoveries, preparing them for clinical translation. It operates with a 1-10 employee team under CEO Maurice T. Hampton.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Development

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)

akta.pro secondary industry

Translational Medicine & Biomarkers (HLAIALAF)

Keywords

• Biopharmaceutical development
• Clinical translation
• Therapeutic discovery
• Drug development
• Asset commercialization

Headquarters

HQ city

Philadelphia

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations

Core offering

Telesis Therapeutics develops and commercializes breakthrough scientific discoveries and prepares these assets for clinical translation. The company operates in the early-stage biopharmaceutical value chain, advancing novel scientific findings into clinical-stage therapeutic candidates for further development.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves2 records

Broad incumbents

• Adaptimmune Therapeutics: Established cell therapy biotech commercializing engineered TCR therapies for solid tumors. Comparable as a company whose original business was translating cell therapy science into clinical assets, representing the scaled version of Telesis's translation thesis.

Emerging players

• NeoGenesis Therapeutics: Small biotech focused on translating discovery-stage biologic science into therapeutic candidates. Comparable to Telesis in size and translation-centric business model, although more oriented toward biologics discovery.
• iECURE: Early-stage gene editing biotech focused on translating in vivo editing discoveries into clinical programs. Comparable asset translation approach at a similar pre-IND or early-clinical maturity, though in a different modality than Telesis.
• Century Therapeutics: Philadelphia-based biotech developing iPSC-derived cell therapies. Comparable regional and translation focus, though operating at a more advanced clinical stage than Telesis Therapeutics.

Direct peers

• Axol Bioscience: Small US/UK translational biotech working on cell-based discovery and clinical translation platforms. Comparable to Telesis Therapeutics as a focused, discovery-to-translation entity advancing scientific discoveries toward clinical assets.
• Carisma Therapeutics: Philadelphia-based biotech translating macrophage cell therapy discoveries from Penn into clinical programs. Relevant peer due to Philadelphia base and academic-to-clinical translation strategy comparable to Telesis.
• Tmunity Therapeutics: Philadelphia-based biotech translating academic discoveries (cell therapy and gene therapy) from Penn into clinical programs. Directly comparable to Telesis Therapeutics given shared Philadelphia location and academic translation model.
• Cabaletta Bio: Philadelphia-area translational biotech developing engineered cell therapies based on academic discoveries. Comparable translation-centric model and regional ecosystem as Telesis Therapeutics.

Others

• Charles River Laboratories: Large CRO/CDMO serving translational biotechs with discovery and preclinical development services. Relevant as an enabling service provider that a small translation-focused company like Telesis would likely depend on to advance discoveries toward IND.
• Thermo Fisher Scientific: Global life sciences tools and CDMO provider including Patheon and PPD CRO services. Comparable as a downstream partner a small biotech like Telesis would engage to manufacture and clinically translate discovery-stage assets.

Market position

Strengths3 records

Weaknesses5 records

Competitive moat1 record

Key risks5 records

Key highlights4 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Telesis Therapeutics